Navigation Links
Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
Date:12/1/2008

t, rotating and early riser), travel across time zones, delayed sleep phase syndrome, advanced phase syndrome and the non-24-hour sleep-wake syndrome in the blind. These disorders represent a large public health problem and, as presented in the 2006 Institute of Medicine (IOM) report on sleep disorders(5), the annual economic impact of sleep problems due to night shift work alone is estimated to exceed $65 billion.

The novel circadian regulator tasimelteon holds promise for the treatment of patients with misalignments of the body clock. The work presented in The Lancet examines the potential application in sleep disorders. Additional clinical trials will have to be conducted to examine the role of circadian regulators in the treatment of other disorders such as depression, nondipper hypertension(3)(4), and others.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failur
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
3. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
4. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
5. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
6. CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease
7. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
8. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
9. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
10. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
11. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015  The efficacy of ... highlighted in a recently published study 1 of ... prevention research team, including Curtis Donskey , M.D.  ... run for the same length of time from the ... (PU-UV) unit.  The results showed surprisingly low pathogen kill ...
(Date:3/31/2015)... , March 31, 2015  Frequentz Inc., a global ... a white paper to help the pharmaceutical industry understand ... Supply Chain Security Act (DSCSA). The white paper, "From ... the GS1 EPCIS Standard(s) and Implementation Plan ... the product tracing requirements that need to occur between ...
(Date:3/31/2015)... March 31, 2015  Dr. Renu Razdan of ... World Orphan Drug Congress in April to discuss the latest, ... process and orphan drugs below: India,s ... the Ministry of Health that if a new drug is ... be obtained in India with waiver ...
Breaking Medicine Technology:VA Funded Study Validates Continuous UV-C Technology For Pathogen Reduction 2VA Funded Study Validates Continuous UV-C Technology For Pathogen Reduction 3VA Funded Study Validates Continuous UV-C Technology For Pathogen Reduction 4Frequentz Releases White Paper Addressing DSCSA's Current & Future Impact 2Frequentz Releases White Paper Addressing DSCSA's Current & Future Impact 3Max Neeman to Discuss India's Orphan Drug Regulations at WOD 2015 2
(Date:3/31/2015)... Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ) ... fraud resulted in $45.4 million in savings -- identified ... -- in 2014. The $45.4 million represents the highest/recovery ... Special Investigations Unit (SIU) in 1983. Since 2005, ... , “Our SIU has progressively enhanced Horizon’s analytics ...
(Date:3/31/2015)... March 31, 2015 An individual’s meniscus ... important ligaments in the leg providing stability, load bearing ... study at today’s Specialty Day meeting of the American ... MRI data to determine the potential for biologic healing ... understood about the healing of meniscus tears when a ...
(Date:3/31/2015)... March 31, 2015 Burns Engineering announces 3-Day ... for the Food & Beverage, Pharmaceutical and Biotech markets. ... are ASME-BPE compliant and are now available as part of ... running. , The S01 and S03 with 1/8” ... Ferrule process connections used in process lines 1/4” and larger. ...
(Date:3/31/2015)... The report “Coagulation/Hemostasis Analyzer Market ... Type (APTT, Prothrombin Time/INR, D-Dimer, Fibrinogen), Technology (Mechanical, ... analyzes and studies the major market drivers, restraints, ... and the Rest of the world (RoW). ... to reach $3.58 billion by 2019 from $2.4 ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 ... that specializes in providing online solutions to ... today it has achieved full accreditation for ... Network Accreditation Program (HNAP) from the Electronic ... EHNAC’s HNAP accreditation runs in two-year increments ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Saves Members, Health System a Record $45.4 Million through Anti-fraud Efforts 2Health News:New Way to Evaluate Meniscus Tear Outcomes 2Health News:Burns Engineering Now Offers 3-Day Quick Ship on Sanitary RTDs and Thermocouples 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 2Health News:DentalXChange Achieves EHNAC Healthcare Network Accreditation for Fifth Consecutive Time 3
... Medial Saude S/A,(BOVESPA: MEDI3) (MEDIAL SAUDE) announces the following webcast: , , ... Friday, August 14, 2009 at 12:00 PM ET, ... Live over the Internet -- Simply log on to the web at the, ... Conference call dial-in phone numbers:, Toll-free from the US: (1 888) ...
... , , INDIANAPOLIS, Aug. 3 ... by Adventist Health System as its exclusive clearinghouse for physicians. ... portal-based clearinghouse/Revenue Cycle Management Services to improve Adventist Health System,s ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090701/RMLOGO ...
... ... Plastic Surgery Societies Reveals Surprising Answers , ... New York, NY and Arlington Heights, IL (Vocus) August 3, 2009 -- What ... person. That,s just one finding from a recent consumer survey conducted on the BeautyforLife ...
... INCLINE VILLAGE, Nev., Aug. 3 PDL BioPharma, Inc. (PDL) ... E. ("Barry") Selick, Ph.D., to the Company,s Board of Directors. , ... and his extensive knowledge of PDL,s humanization technology will allow him ... seek to maximize the value of our antibody humanization patents and ...
... HATBORO, Pa., August 3 InfoLogix, Inc. ... of enterprise mobility solutions for the healthcare and commercial industries, ... healthcare providers, the InfoLogix M24 mobile clinical assistant: a powerful ... patient information at the point-of-care. , , ...
... LITTLE FALLS, N.J., Aug. 3 CANTEL MEDICAL ... Purification subsidiary, has continued the expansion of its water purification and ... Systems Int,l, LLC. G.E.M. designs, builds, installs and services high ... The acquired business had pre-acquisition revenues of approximately $3.5 million. ...
Cached Medicine News:Health News:RealMed Named Exclusive Medical Claims Clearinghouse for Physicians by Adventist Health System 2Health News:RealMed Named Exclusive Medical Claims Clearinghouse for Physicians by Adventist Health System 3Health News:How Do Our Attitudes About Beauty Change As We Age? 2Health News:How Do Our Attitudes About Beauty Change As We Age? 3Health News:How Do Our Attitudes About Beauty Change As We Age? 4Health News:PDL BioPharma Elects Barry Selick to Its Board of Directors 2Health News:New InfoLogix M24 Mobile Clinical Assistant Will Enable Hospitals to Access Electronic Medical Records (EMR) Directly at the Point of Care 2Health News:New InfoLogix M24 Mobile Clinical Assistant Will Enable Hospitals to Access Electronic Medical Records (EMR) Directly at the Point of Care 3Health News:Cantel Medical's Mar Cor Purification Subsidiary Acquires G.E.M. Water Systems ... Establishing a Nationwide Reach in Water Treatment 2Health News:Cantel Medical's Mar Cor Purification Subsidiary Acquires G.E.M. Water Systems ... Establishing a Nationwide Reach in Water Treatment 3
The unique design of the TWINFIX Suture Anchors combines high resistance to pullout from our patented thread design with optimal knot tying from the DURABRAID suture....
... Micro Anchor is the smallest, strongest ... flexibility in placement into even the ... with 3-0 or 4-0 ETHIBOND EXCEL ... or cutting swaged needles. The kit ...
The Mini Anchor is an exceptionally strong, versatile anchor. This anchor comes in either a load-your-own or QUICKANCHOR format, preloaded on either 2/0 or 0 ETHIBOND EXCEL suture with swaged needles...
... Threaded Anchors (3.0mm) are ideal for soft tissue ... surgical applications. The FASTIN threaded anchor technology offers ... surgical sites. If you need a threaded anchor ... the FASTIN anchor is the anchor for you. ...
Medicine Products: